A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (REMoDL-B)

• Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

• Overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Event-free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Disease-free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Time to progression [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Response duration [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Complete and overall response rates [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  
• Evaluation of toxicity (according to CTCAE version 4.0) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  
• Quality of life and assessment of peripheral neuropathy [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  

REMoDLB is a trial which aims to determine whether the addition of bortezomib (a drug that blocks the action of cellular complexes that break down proteins) to standard combination chemotherapy (called R-CHOP) improves how long patients with diffuse large B cell lymphoma survive without a recurrence of the disease. Results from recent research have suggested that patients can be divided into two biologically distinct subgroups labeled GCB (germinal centre derived B-cells like) and ABC (activated peripheral B-cells like).

GCB patients tend to do well with standard combination chemotherapy, but ABC patients have the majority of treatment failures. It is thought that ABC patients will benefit most from the addition of bortezomib.

The trial will be discussed with the patient. They will be asked to consent to molecular profiling of their tumour block whilst they have some time to consider whether they wish to enter the main trial. This will allow more time for this sample to be analysed and their particular biological subgroup to be determined.

All patients consenting to enter the main study will be given an initial cycle of RCHOP chemotherapy. Within each subgroup (ABC or GCB) patients will be randomly assigned to receive either RCHOP or RCHOP and bortezomib to ensure that the same number of each biological subgroup will receive the two treatments. All patients will then have 5 cycles of their assigned treatment regimen (either RCHOP or RCHOP and bortezomib). All patients will be followed up for a period of five years once they have completed their chemotherapy. The GCB group receiving RCHOP and bortezomib will be regularly checked to see if the new treatment is improving survival without recurrence of the disease. If the addition of bortezomib is not found to be beneficial for this group of patients this part of the trial will be stopped and all GCB patients will receive the standard treatment only (RCHOP).

It is anticipated that between 560 and 800 patients will be randomly allocated to the two treatments, the exact number depends on whether the GCB group receiving RCHOP and bortezomib is stopped or not.